Clinical Trial Update: A Study of the Pharmacokinetics/Pharmacodynamics of GK Activator (2) in Type 2 Diabetes Patients With Hepatic Impairment. [Phase 1]

View source ↗

Summary

The Phase 1 PK/PD study of GK Activator (2) in patients with Type 2 diabetes and hepatic impairment has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• GK Activator (2)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: TERMINATED